SESEN BIO, INC Current Ratio 2012-2021 | SESN

SESEN BIO, INC current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
SESEN BIO, INC Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.18B $0.02B 9.30
2021-03-31 $0.13B $0.02B 7.29
2020-12-31 $0.06B $0.02B 3.48
2020-09-30 $0.05B $0.01B 5.05
2020-06-30 $0.04B $0.01B 6.37
2020-03-31 $0.05B $0.01B 6.09
2019-12-31 $0.05B $0.01B 6.39
2019-09-30 $0.06B $0.01B 6.54
2019-06-30 $0.07B $0.01B 8.50
2019-03-31 $0.05B $0.01B 6.44
2018-12-31 $0.05B $0.01B 8.47
2018-09-30 $0.06B $0.01B 9.05
2018-06-30 $0.06B $0.01B 14.07
2018-03-31 $0.02B $0.01B 3.88
2017-12-31 $0.02B $0.01B 3.17
2017-09-30 $0.01B $0.00B 2.75
2017-06-30 $0.02B $0.00B 4.27
2017-03-31 $0.02B $0.00B 6.50
2016-12-31 $0.03B $0.00B 6.51
2016-09-30 $0.03B $0.01B 5.08
2016-06-30 $0.01B $0.00B 2.94
2016-03-31 $0.01B $0.00B 6.05
2015-12-31 $0.04B $0.01B 4.79
2015-09-30 $0.05B $0.01B 6.18
2015-06-30 $0.05B $0.01B 9.95
2015-03-31 $0.05B $0.01B 9.94
2014-12-31 $0.05B $0.01B 10.46
2014-09-30 $0.04B $0.01B 5.58
2014-06-30 $0.05B $0.01B 7.64
2014-03-31 $0.05B $0.01B 8.63
2013-12-31 $0.01B $0.01B 1.50
2013-09-30 $0.00B 0.00
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.01B $0.00B 4.54
2011-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.225B $0.011B
Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven Biotherapeutics, is based in Massachusetts, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76